Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EV68-228-N
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Not Applicable
Deal Type : Not Applicable
KBio Gets FDA IND Clearance for EV68-228-N in Acute Flaccid Myelitis Phase 1
Details : EV68-228-N, a human monoclonal IgG1 against the capsid of enterovirus D68 (EV-D68) designed as an intravenous therapeutic for the treatment of acute flaccid myelitis (AFM).
Brand Name : EV68-228-N
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 28, 2024
Lead Product(s) : EV68-228-N
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Monoclonal Antibody
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Leaf Expression Systems
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will support the activities as development of new technologies to improve ongoing research activities, enhance expression and production of proteins within plants and for development of new approaches and plant lines to increase plant-d...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 28, 2022
Lead Product(s) : Monoclonal Antibody
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Leaf Expression Systems
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Monoclonal Antibody-based Therapy
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : ZabBio
Deal Size : Undisclosed
Deal Type : Partnership
KBio Announces Strategic Partnership with ZabBio to Discover and Develop Antibody Therapeutics
Details : Under the terms of the agreement, KBio will have development rights to select assets within ZabBio’s current pipeline of antibody therapies – including a late-stage preclinical anti-fungal mAb – as well as future products discovered under the colla...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 13, 2022
Lead Product(s) : Monoclonal Antibody-based Therapy
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : ZabBio
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?